Clinical Trials | October 31, 2025
Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients in kidney and liver transplantation
Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs
Quest Diagnostics’ blood-based test panels demonstrate confirmatory accuracy, potentially reducing the need for PET imaging
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
The antibody was designed and developed at Abzena’s Cambridge, UK,
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
In the next five years, an additional 75,000 seats are expected to be added across both undergraduate and postgraduate levels
The event will be attended by 35,000+ industry professionals
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
Subscribe To Our Newsletter & Stay Updated
